The TREAT-NMD Advisory Committee for Therapeutics (TACT): An Innovative de-Risking Model to Foster Orphan Drug Development
eCOA Consortium Announces New Article for Applied Clinical Trials C-Path’s eCOA Consortium is pleased to announce that “Evaluating the Use of Backup Solutions for ePRO Systems” has been publ
C-Path Appoints Dr. Amanda Klein as Executive Director for CPLD and CPA-1 Consortia TUCSON, Ariz., April 17, 2024 — Critical Path Institute (C-Path) today announced the appointment of Amanda Klein, Pharm.D., as E
C-Path Awarded FDA Drug Development Tool Research Grant to Develop a Qualification Plan for the PROMIS® Short Form v2.1—Physical Function-Multiple Sclerosis 15a (PROMIS PFMS—15a) C-Path’s Patient-Reported Outcome (PRO) Consortium announced today it has been awarded a U.S. Food and Drug Administratio
Critical Path Institute’s Patient-Reported Outcome (PRO) Consortium: A Translatability Assessment Context
C-Path’s PKDOC Presentation on Fluid-Based Biomarkers Critical Path Institute’s John-Michael Sauer, Ph.D. presents information on fluid-based biomarkers and how they can be applied
C-Path Forms Data Collaboration with International Niemann-Pick Disease Registry (INPDR) to Propel Niemann-Pick Disease Research Forward TUCSON, Ariz. April 17, 2024 — Critical Path Institute (C-Path), a leader in advancing rare disease research, today announced a